Document Detail

Impact of bevacizumab chemotherapy on craniotomy wound healing.
MedLine Citation:
PMID:  21142749     Owner:  NLM     Status:  MEDLINE    
OBJECT: The FDA approval of bevacizumab for recurrent glioblastoma has resulted in its increased use in this patient population. Phase II trials reported 4%-6% impaired wound healing for bevacizumab initiated postoperatively. The effect of preoperative bevacizumab on subsequent craniotomy healing has not been addressed.
METHODS: The authors retrospectively reviewed the cases of patients who underwent craniotomy for recurrent glioblastoma between 2005 and 2009, evaluating bevacizumab therapy/duration and healing complications (dehiscence, pseudomeningocele, CSF leak, and wound/bone infection). The Wilcoxon rank-sum test and Kruskal-Wallis test were used to compare continuous variables between groups. The Fisher exact test was used to assess for an association between categorical variables, including the comparison of wound-healing complication rates. Logistic regression models were used to estimate odds ratios of wound-healing complications while adjusting for baseline variables.
RESULTS: Two hundred nine patients underwent a second craniotomy (161 patients) or third craniotomy (48 patients) for recurrent glioblastoma. Twenty-six individuals (12%) developed wound-healing complications. One hundred sixty-eight patients received no bevacizumab, 23 received preoperative bevacizumab, and 18 received postoperative bevacizumab. Significantly more patients receiving preoperative bevacizumab developed healing complications (35%) than non-bevacizumab-treated patients (10.0%, p = 0.004). Postoperative bevacizumab was associated with 6% impaired healing, not significantly different from non-bevacizumab-treated controls (p = 1.0). Preoperative bevacizumab treatment duration (weeks) did not influence healing (OR 0.98, p = 0.55). More healing complications occurred in patients receiving preoperative bevacizumab than in non-bevacizumab-treated controls before the third craniotomy (44% vs 9%, p = 0.03).
CONCLUSIONS: Although subject to the limitations of a retrospective study, we demonstrate that preoperative bevacizumab treatment resulted in impaired healing after a second and third craniotomy, compared with minimal effect of postoperative bevacizumab. This effect is more striking for the third craniotomy and for a shorter delay between bevacizumab and surgery. These complications should be acknowledged as increased bevacizumab use results in more post-bevacizumab-treated patients in whom surgery for recurrent glioblastoma is considered. Based on these results, the authors recommend performing repeated craniotomy more than 28 days after last administered dose of bevacizumab whenever possible.
Aaron J Clark; Nicholas A Butowski; Susan M Chang; Michael D Prados; Jennifer Clarke; Mei-Yin C Polley; Michael E Sughrue; Michael W McDermott; Andrew T Parsa; Mitchel S Berger; Manish K Aghi
Related Documents :
21533539 - Major functional deficits persist 2 years after acute achilles tendon rupture.
21372269 - Preprocedural clinical parameters determining perimitral conduction time during mitral ...
21498039 - Postoperative limb alignment and its determinants after minimally invasive oxford media...
21328679 - Safety and efficacy of drug eluting stents compared with bare metal stents for saphenou...
17418259 - Intranasal corticosteroid use is associated with lower rates of bacterial recovery in c...
9385949 - Synostotic frontal plagiocephaly: anthropometric comparison of three techniques for sur...
23295819 - Epidemiology of oestrus ovis (diptera: oestridae) in sheep in botucatu, state of são p...
21436739 - Biomechanical study of patient positioning: influence of lower limb positioning on spin...
678179 - Corneal complications after closed vitrectomy through the pars plana.
Publication Detail:
Type:  Journal Article     Date:  2010-12-10
Journal Detail:
Title:  Journal of neurosurgery     Volume:  114     ISSN:  1933-0693     ISO Abbreviation:  J. Neurosurg.     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-06-02     Completed Date:  2011-08-05     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0253357     Medline TA:  J Neurosurg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1609-16     Citation Subset:  AIM; IM    
Department of Neurological Surgery, University of California, San Francisco, California 94143-0112, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Analysis of Variance
Antibodies, Monoclonal / pharmacology,  therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / pharmacology,  therapeutic use*
Brain Neoplasms / drug therapy*,  surgery
Glioblastoma / drug therapy*,  surgery
Middle Aged
Neoplasm Recurrence, Local / drug therapy*,  surgery
Retrospective Studies
Treatment Outcome
Wound Healing / drug effects*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hydrocephalus associated with vestibular schwannomas: management options and factors predicting the ...
Next Document:  Endoscopic supraorbital extradural approach to the cavernous sinus: a cadaver study.